Will Pfizer's Q3 2026 EPS miss Wall Street consensus by 13 Oct 2026?
Posted 2026-09-29 — 14 days before the deadline, stated before the outcome.
Pfizer is a multinational pharmaceutical company whose quarterly earnings are closely monitored by investors. Wall Street consensus estimates represent the average financial projections made by analysts for a company's performance.
The claim
Pfizer reports a quarterly net income per share below the Wall Street consensus estimate for the current period.
Reasoning trace
- Significant revenue decline from the normalization of COVID-19 vaccine and therapeutic sales (LOE trough).
- Headwinds from patent expirations on key small-molecule assets.
- Aggressive cost-cutting measures not yet fully offsetting the revenue drop in the short term.
Evidence so far
0 confirming · 0 denying signals · 1 verified · 0 broken assumptions. The evidence itself is part of the full dossier.
Probability history
Updated 1 time since mint (last on 2026-09-29) — 70% at mint → 79% today.
What to watch
- leading indicator Pfizer announces a preliminary revenue guidance or warning indicating Q3 2026 sales will be below analyst expectations
- leading indicator Financial data providers (e.g., Bloomberg, Refinitiv) show a downward revision trend in Pfizer's Q3 2026 consensus EPS estimates in the two weeks prior to the earnings date
- leading indicator Pfizer's Q3 2026 vaccine and therapeutic sales are reported to be significantly lower than the same period in 2025
The full dossier behind this prediction — the evidence trail, the risk analysis, the monetization scenarios — is available on request: [email protected].
Probabilities are calibrated against the system's own resolved history; after the deadline the outcome is resolved and audited — including the calls we get wrong. Nothing on this page is investment advice.